An FBXO40 knockout generated by CRISPR/Cas9 causes muscle hypertrophy in pigs without detectable pathological effects

Biochem Biophys Res Commun. 2018 Apr 15;498(4):940-945. doi: 10.1016/j.bbrc.2018.03.085. Epub 2018 Mar 15.

Abstract

The regulatory function of Fbxo40 has been well characterized in mice. As a key component of the SCF-E3 ubiquitin ligase complex, Fbxo40 induces IRS1 ubiquitination, thus inactivating the IGF1/Akt pathway. The expression of Fbxo40 is restricted to muscle, and mice with an Fbxo40 null mutation exhibit muscle hypertrophy. However, the function of FBXO40 has not been elucidated in pigs, and it is not known whether FBXO40 mutations affect their health. We therefore generated FBXO40 knockout pigs using somatic cell nuclear transfer (SCNT) technology. CRISPR/Cas9 technology was combined with G418 selection, making it possible to generate donor cells at an efficiency of 75.86%. In muscle from FBXO40 knockout pigs, IRS1 levels were higher, and the IGF1/Akt pathway was stimulated. Mutant animals also had approximately 4% more muscle mass compared to WT controls. The knockout pigs developed normally and no pathological changes were found in major organs. These results demonstrate that FBXO40 is a promising candidate gene for improving production traits in agricultural livestock and for developing therapeutic interventions for muscle diseases.

Keywords: CRISPR/Cas9; FBXO40; Muscle hypertrophy; Pig.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CRISPR-Cas Systems
  • F-Box Proteins / genetics*
  • Gene Knockout Techniques
  • Hypertrophy / etiology*
  • Hypertrophy / genetics
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin-Like Growth Factor I / metabolism
  • Muscles / pathology*
  • Oncogene Protein v-akt / metabolism
  • Sus scrofa

Substances

  • F-Box Proteins
  • Insulin Receptor Substrate Proteins
  • Insulin-Like Growth Factor I
  • Oncogene Protein v-akt